CN1330670C - Process for extracting polygonatum polysaccharides, preparing process for medical preparation and use thereof - Google Patents
Process for extracting polygonatum polysaccharides, preparing process for medical preparation and use thereof Download PDFInfo
- Publication number
- CN1330670C CN1330670C CNB2004100228635A CN200410022863A CN1330670C CN 1330670 C CN1330670 C CN 1330670C CN B2004100228635 A CNB2004100228635 A CN B2004100228635A CN 200410022863 A CN200410022863 A CN 200410022863A CN 1330670 C CN1330670 C CN 1330670C
- Authority
- CN
- China
- Prior art keywords
- polygonatum
- polysaccharide
- precipitate
- hours
- add
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000756042 Polygonatum Species 0.000 title claims abstract description 68
- 150000004676 glycans Chemical class 0.000 title claims abstract description 49
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 49
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 49
- 238000000034 method Methods 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title abstract description 17
- 230000008569 process Effects 0.000 title description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 52
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 31
- 239000000284 extract Substances 0.000 claims abstract description 19
- 239000002244 precipitate Substances 0.000 claims abstract description 16
- 239000002775 capsule Substances 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims abstract description 10
- 239000012153 distilled water Substances 0.000 claims abstract description 9
- 239000000843 powder Substances 0.000 claims abstract description 9
- 238000005406 washing Methods 0.000 claims abstract description 9
- 239000006228 supernatant Substances 0.000 claims abstract description 8
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 7
- 238000000605 extraction Methods 0.000 claims abstract description 6
- 230000002829 reductive effect Effects 0.000 claims abstract description 6
- 239000008187 granular material Substances 0.000 claims abstract description 5
- 238000003756 stirring Methods 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims description 30
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 24
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 20
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 20
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 19
- 229960003943 hypromellose Drugs 0.000 claims description 19
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 12
- 239000008101 lactose Substances 0.000 claims description 12
- 235000019359 magnesium stearate Nutrition 0.000 claims description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 11
- 239000000243 solution Substances 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 9
- 239000004375 Dextrin Substances 0.000 claims description 8
- 229920001353 Dextrin Polymers 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 8
- 235000019425 dextrin Nutrition 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- 239000000741 silica gel Substances 0.000 claims description 7
- 229910002027 silica gel Inorganic materials 0.000 claims description 7
- 238000000108 ultra-filtration Methods 0.000 claims description 7
- 239000012510 hollow fiber Substances 0.000 claims description 6
- 238000012360 testing method Methods 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 238000007689 inspection Methods 0.000 claims description 4
- 229920002521 macromolecule Polymers 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 2
- 235000017166 Bambusa arundinacea Nutrition 0.000 claims 1
- 235000017491 Bambusa tulda Nutrition 0.000 claims 1
- 241001330002 Bambuseae Species 0.000 claims 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 claims 1
- 102000011759 adducin Human genes 0.000 claims 1
- 108010076723 adducin Proteins 0.000 claims 1
- RJGDLRCDCYRQOQ-UHFFFAOYSA-N anthrone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 RJGDLRCDCYRQOQ-UHFFFAOYSA-N 0.000 claims 1
- 239000011425 bamboo Substances 0.000 claims 1
- 238000009835 boiling Methods 0.000 claims 1
- 239000010977 jade Substances 0.000 claims 1
- 150000002772 monosaccharides Chemical class 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 238000007639 printing Methods 0.000 claims 1
- 239000007779 soft material Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 32
- 239000008280 blood Substances 0.000 abstract description 32
- 239000007788 liquid Substances 0.000 abstract description 14
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 9
- 201000001421 hyperglycemia Diseases 0.000 abstract description 6
- 239000003826 tablet Substances 0.000 abstract description 6
- 239000006189 buccal tablet Substances 0.000 abstract description 3
- 239000007910 chewable tablet Substances 0.000 abstract description 3
- 239000007919 dispersible tablet Substances 0.000 abstract description 3
- 239000008297 liquid dosage form Substances 0.000 abstract description 3
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000007909 solid dosage form Substances 0.000 abstract 1
- 235000008737 Polygonatum biflorum Nutrition 0.000 description 46
- 238000011282 treatment Methods 0.000 description 26
- 241001465754 Metazoa Species 0.000 description 25
- 238000002156 mixing Methods 0.000 description 18
- 150000002632 lipids Chemical class 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 11
- 239000008802 xuezhikang Substances 0.000 description 10
- 238000010171 animal model Methods 0.000 description 9
- 239000008882 Tang Maikang Chemical group 0.000 description 8
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical group C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 7
- 230000002218 hypoglycaemic effect Effects 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical group C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 7
- 239000000463 material Substances 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 108010007622 LDL Lipoproteins Proteins 0.000 description 5
- 102000007330 LDL Lipoproteins Human genes 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000001291 vacuum drying Methods 0.000 description 5
- 210000000709 aorta Anatomy 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 210000000497 foam cell Anatomy 0.000 description 4
- 235000009200 high fat diet Nutrition 0.000 description 4
- 239000002075 main ingredient Substances 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 201000002282 venous insufficiency Diseases 0.000 description 4
- 102100040214 Apolipoprotein(a) Human genes 0.000 description 3
- 101710115418 Apolipoprotein(a) Proteins 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 206010013786 Dry skin Diseases 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 229920002683 Glycosaminoglycan Polymers 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000003524 antilipemic agent Substances 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000011122 softwood Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 3
- 229960001052 streptozocin Drugs 0.000 description 3
- 239000007916 tablet composition Substances 0.000 description 3
- 239000008399 tap water Substances 0.000 description 3
- 235000020679 tap water Nutrition 0.000 description 3
- 210000004026 tunica intima Anatomy 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 235000020985 whole grains Nutrition 0.000 description 3
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 2
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- ILPUOPPYSQEBNJ-UHFFFAOYSA-N 2-methyl-2-phenoxypropanoic acid Chemical compound OC(=O)C(C)(C)OC1=CC=CC=C1 ILPUOPPYSQEBNJ-UHFFFAOYSA-N 0.000 description 2
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 2
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229940046011 buccal tablet Drugs 0.000 description 2
- 229940068682 chewable tablet Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 230000000055 hyoplipidemic effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229920001206 natural gum Polymers 0.000 description 2
- 238000007427 paired t-test Methods 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000452 restraining effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 2
- 229950005143 sitosterol Drugs 0.000 description 2
- 235000015500 sitosterol Nutrition 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- XDIYNQZUNSSENW-UUBOPVPUSA-N (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XDIYNQZUNSSENW-UUBOPVPUSA-N 0.000 description 1
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- IUKHSWVQCORLGA-AYXADEGOSA-N (3s,4r,5r)-1,3,4,5,6-pentahydroxyhexan-2-one Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO.OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO IUKHSWVQCORLGA-AYXADEGOSA-N 0.000 description 1
- AJDIZQLSFPQPEY-UHFFFAOYSA-N 1,1,2-Trichlorotrifluoroethane Chemical compound FC(F)(Cl)C(F)(Cl)Cl AJDIZQLSFPQPEY-UHFFFAOYSA-N 0.000 description 1
- AGRCPNMCOXLKFO-BDVNFPICSA-N 1-methyl-1-nitroso-3-[(2r,3r,4s,5r)-3,4,5,6-tetrahydroxy-1-oxohexan-2-yl]urea Chemical compound O=NN(C)C(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO AGRCPNMCOXLKFO-BDVNFPICSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 241000427159 Achyranthes Species 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 206010065558 Aortic arteriosclerosis Diseases 0.000 description 1
- 241000050051 Chelone glabra Species 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 1
- 235000009685 Crataegus X maligna Nutrition 0.000 description 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 1
- 235000009486 Crataegus bullatus Nutrition 0.000 description 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 1
- 235000009682 Crataegus limnophila Nutrition 0.000 description 1
- 235000004423 Crataegus monogyna Nutrition 0.000 description 1
- 240000000171 Crataegus monogyna Species 0.000 description 1
- 235000002313 Crataegus paludosa Nutrition 0.000 description 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 1
- AEMOLEFTQBMNLQ-DTEWXJGMSA-N D-Galacturonic acid Natural products O[C@@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-DTEWXJGMSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229920002670 Fructan Polymers 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 240000006509 Gynostemma pentaphyllum Species 0.000 description 1
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical group CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001633680 Polygonatum odoratum Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229940123934 Reductase inhibitor Drugs 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 201000001962 aortic atherosclerosis Diseases 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000002279 cholagogic effect Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000008753 endothelial function Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000003516 hyperlipidaemic effect Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000009427 jiangzhi Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000008604 lipoprotein metabolism Effects 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 229930002600 steroidal saponin Natural products 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000007693 zone electrophoresis Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种玉竹多糖的提取方法、药物制剂制备方法及其用途。玉竹多糖的提取方法是将玉竹生药切成小块，加放4～16倍量水，煮沸提取1-4小时，提取液过滤，残渣另加入6～12倍的水，煮沸提取1～2小时，提取液过滤，将2次提取液合并，离心处理，得上清液减压浓缩，至相对密度1.08～1.25(45-60℃)，放置至室温，加入4～8倍的95%的乙醇液，搅拌静置12-48小时，分离取沉淀物，加冷蒸馏水0.5～2倍洗涤，沉淀物加热蒸馏水溶解，加入0.5～4倍量的95%乙醇沉淀，静置12～48小时，分取沉淀物，以0.5～3倍量的95%乙醇洗涤三次，弃去醇洗液，沉淀物冷冻干燥一段时间后，再在温度为60℃下真空干燥至干，取出、粉碎，得白色粉末。玉竹多糖药物制剂的制备方法是将制得的玉竹多糖加入适当的辅料，可以制备成片剂、胶囊剂、颗粒剂、口含片、咀嚼片、分散片类的固体剂型，也可以制备成口服液、合剂类的液体剂型。玉竹多糖药物制剂用于降血糖、特别是降血脂，对高血脂及高血糖病人，可以起到降血糖和降血脂作用。The invention relates to a method for extracting polysaccharides from polygonatum polysaccharides, a method for preparing pharmaceutical preparations and uses thereof. The extraction method of Polygonatum Polysaccharides is to cut Polygonatum polysaccharide into small pieces, add 4 to 16 times the amount of water, boil and extract for 1-4 hours, filter the extract, add 6 to 12 times of water to the residue, boil and extract for 1 to 4 hours. After 2 hours, filter the extract, combine the two extracts, and centrifuge to obtain the supernatant concentrated under reduced pressure to a relative density of 1.08-1.25 (45-60°C), place it at room temperature, and add 4-8 times 95% the ethanol solution, stir and stand for 12-48 hours, separate the precipitate, add 0.5 to 2 times of cold distilled water to wash, dissolve the precipitate with distilled water, add 0.5 to 4 times the amount of 95% ethanol to precipitate, and stand for 12 to 48 hours , separate the precipitate, wash three times with 0.5 to 3 times the amount of 95% ethanol, discard the alcohol washing solution, freeze-dry the precipitate for a period of time, and then dry it in vacuum at a temperature of 60°C until dry, take it out, and crush it to obtain White powder. The preparation method of the Polygonatum polysaccharide pharmaceutical preparation is to add the obtained Polygonatum polysaccharide into appropriate excipients, which can be prepared into solid dosage forms such as tablets, capsules, granules, buccal tablets, chewable tablets, and dispersible tablets, and can also be prepared Liquid dosage form of oral liquid and mixture. Polygonatum polysaccharide pharmaceutical preparations are used to lower blood sugar, especially blood fat, and can lower blood sugar and blood fat in patients with hyperlipidemia and hyperglycemia.
Description
Technical field
The present invention relates to extracting method, preparation of pharmaceutical formulations method of a kind of fragrant solomonseal rhizome polyoses and uses thereof.
Background technology
Cardiovascular disorder has become one of main disease that influences China's people ' s health at present, hyperlipidaemia is a kind of common cardiovascular disorder, it is again the important paathogenic factor of atherosclerosis (AS) and coronary heart disease, hypolipidemic can delay to rotate with Partial Inverse the progress of pulse atherosclerosis focus, prevent plaque rupture and improve endothelial function, and obviously reduce the M ﹠ M of cardiovascular diseases.Lipid lowering agent can be divided into by its effect at present: the medicine that 1. mainly reduces blood cholesterol: comprise cholic acid complexing agent, hydroxyl first pentanedioyl acyl coenzyme (HMG-CoA) reductase inhibitor, steroid derivative, sitosterol etc.; 2. blood TG medicine falls: comprise nicotinic acid class, fibric acid, polyunsaturated fatty acid class, mucopolysaccharide and polyose etc.; 3. the medicine that has lipoid peroxidization resistant; 4. other lipid lowering agents.Wherein first kind medicine has peculiar smell or gastrointestinal reaction mostly and takes inconvenience, and costs an arm and a leg, and takes the absorption that can hinder fat-soluble A, D, E, K for a long time, uses not extensive.At present clinically widespread use be statins, belong to the HMG-CoA reductase inhibitor, transfer the blood fat determined curative effect, but prolonged application has hepatotoxicity and other side effects.In addition; nicotinic acid class, mucopolysaccharide and polyose Antiatherosclerosis medicine; as heparin; have effects such as the blood fat of accent, antithrombotic, protection arterial endothelium, inhibition arterial wall smooth muscle cell hyperplasia; but because of its blood coagulation resisting function strong; can cause the hemorrhage untoward reaction of Denging, and transformation period weak point in the body, limited its clinical application.Steroid derivative, sitosterol, fibric acid, polyunsaturated fatty acid class, probucol, vitamin medicaments then lack clinical widely support.Chinese medicine is very promising aspect the treatment of hyperlipidemia, forms unusually from improving lipoprotein metabolism and lipoprotein, and Chinese medicine has the pharmacological action characteristics that chemical synthetic drug does not possess.Hyperlipidaemia belongs to the category of traditional Chinese medicine " phlegm ", and that the rules of treatment have promoting digestion and removing indigestion, invigorating spleen to remove dampness, Wen Yangyi unit, the phlegm that slits is dispelled is turbid, the clearing liver cholagogic, protect that the moonization is turbid, diuresisization is turbid, lead to internal organs and wash turbid, the stagnation resolvation fat etc. of dispelling.The single reducing blood-fat Chinese medicine of having reported has genseng, radix bupleuri, the root of large-flowered skullcap, gynostemma pentaphylla, the root of bidentate achyranthes, garlic, hawthorn etc., and compound hypolipidemic Chinese medicine has dachaihu decoction, Herba Sidae Rhombifoliae soup etc.Gone on the market Chinese medicine and prescribed preparation has SHANZHAJING JIANGZHI PIAN, Xuezhikang etc., but effective constituent is indeterminate, lacks strict contrast and pharmacological research foundation, and mechanism is unclear, has hindered the further investigation of lipid lowering agent.
Radix polygonati officinalis Polygonatum odoratum (Mill.) Druce is the traditional Chinese medicine of China, and the beginning is stated from Shennong's Herbal, classifies as top gradely, and it derives from the dry rhizome of liliaceous plant radix polygonati officinalis.Main steroidal saponin, polysaccharide, flavones and the anthraquinone class chemical ingredients of containing.Nourishing YIN to relieve dryness is arranged, the function that promotes the production of body fluid to quench thirst.Rats gavaged radix polygonati officinalis preserved material, the hyperglycemia that suprarenin, glucose and tetraoxypyrimidine are caused all has restraining effect.Water-soluble part and propyl carbinol part has obvious restraining effect to U-9889 hyperglycemia mouse in the radix polygonati officinalis methanol extract, infers relevant with the liver glycogen glycolysis.Gavage the radix polygonati officinalis decoction for the experimental hyperlipidemia rabbit or can prevent injection liquid 3 to April blood fat to raise and alleviate atherosclerotic plaque formation, triacylglycerol, cholesterol, beta Lipoprotein are descended in the treatment group.Our experimental study shows that first isolating fragrant solomonseal rhizome polyoses can significantly reduce the blood lipid level of experimental hyperlipidemia animal from the radix polygonati officinalis aqueous extract.
Bibliographical information (see the Yu Jing chief editor. modern Chinese herbal medicine research, the Xueyuan Press, 1998) radix polygonati officinalis contains radix polygonati officinalis mucopolysaccharide (Odoratan), and it consists of D-fructose (D-Fructose), D-seminose (D-Mannose), D-glucose (D-Glucose) and D-galacturonic acid (D-Galacluronicacid); Mol ratio is 6: 3: 1: 1.5, other contains radix polygonati officinalis Polylevulosan (Polygonatum-fructan) A, B, C, D, sugar consist of fructose and glucose.
Polysaccharide has different physiological roles, and cytotoxicity is extremely low.Thereby polysaccharide medicine will have more wide prospect as biological response modifier.At present, from natural product or tunning, separate the preparation polysaccharide, the general using polysaccharide is water-soluble, diluted acid, alkali or salts solution, and be insoluble to alcohol, ether, the characteristics of acetone and other organic solvent, with the low polar organic solvent degreasing decoloring element of crude drug, in order to water the solution extraction polysaccharide of main body with residue then, be cold water, hot water, diluted acid, alkali or salts solution extract, and after extracting solution concentrates, use earlier trichoroacetic acid(TCA), Freon 113 method or Sevag method are removed foreign protein, small molecular weight impurity is removed in dialysis then, concentrates the back freeze-drying or with the methyl alcohol or the ethanol of equivalent or several times, the acetone and other organic solvent precipitation promptly obtains the polysaccharide product.Refining ion-exchange, preparation property zone electrophoresis, gel-filtration, ultrafiltration and preparation property high pressure liquid chromatography methods of adopting of polysaccharide more.Above-mentioned polyoses producing method has the following disadvantages: 1, have darker yellow, brown, and be difficult to decolouring; 2, the complicated time of leaching process is long, cost is high, and the large-scale production difficulty is big; 3, in extracting treating process, used organic solvent; 4, contain monose mostly.In a word, above method is difficult for obtaining highly purified polysaccharide.
Simultaneously, the research of radix polygonati officinalis is also had the following disadvantages: 1, more to the Chinese medicine compound prescription research that contains radix polygonati officinalis, few to single radix polygonati officinalis research; Though the report of 2 and blood fat hypoglycemic relevant for radix polygonati officinalis, the activeconstituents or the activeconstituents group that do not understand the radix polygonati officinalis pharmacological action.3, do not see that fragrant solomonseal rhizome polyoses extracts, preparation method's report; 4, radix polygonati officinalis mainly is enriching yin and nourishing kidney in traditional traditional Chinese medical science, in Chinese medicine compound prescription, can be used for hypoglycemic, relevant for the oral report that blood sugar is fallen after rising of radix polygonati officinalis medicinal extract, and the hyperglycemia that medicinal extract causes suprarenin, glucose, tetraoxypyrimidine has inhibiting report (to see the clear an ancient unit of weight of horse, the Wang Shuling chief editor. the clinical practice Chinese materia medica, Jiangxi science tech publishing house, 2002.), but do not see hypoglycemic, the bibliographical information of reducing blood-fat particularly of fragrant solomonseal rhizome polyoses; 5, do not see report about fragrant solomonseal rhizome polyoses composition, molecular weight and pharmacological action relation.The fragrant solomonseal rhizome polyoses molecular weight of the present invention's preparation is 3000～40, and 000 has hypoglycemic and reducing blood lipid, and purity of polysaccharide height (more than 98%).
Summary of the invention
Technical problem to be solved by this invention is the characteristic according to the contained polysaccharide of radix polygonati officinalis, and exploitation is the former extracting method of expecting the fragrant solomonseal rhizome polyoses that is applicable to industrialized production of high purity fragrant solomonseal rhizome polyoses, preparation of pharmaceutical formulations method and uses thereof with the radix polygonati officinalis crude drug.
The technical scheme that solution the technology of the present invention problem is adopted is that the extracting method of this fragrant solomonseal rhizome polyoses has following two kinds:
1. be that the radix polygonati officinalis crude drug is cut into small pieces, place 4～16 times of water gagings, boil and extracted 1-4 hour, extracting liquid filtering, residue add 6～12 times water in addition, boil and extract 1～2 hour, extracting liquid filtering, No. 2 extracting solutions are merged, and centrifugal treating gets the supernatant liquor concentrating under reduced pressure, to relative density 1.08～1.25 (45-60 ℃), be placed to room temperature, add 4～8 times 95% ethanol liquid, stir and left standstill 12-48 hour, separate taking precipitate, add 0.5～2 times of washing of cold distilled water, throw out heating dissolved in distilled water, 95% ethanol sedimentation of 0.5～4 times of amount of adding, left standstill 12～48 hours, divide taking precipitate,, discard pure washing lotion with 95% washing with alcohol of 0.5～3 times of amount three times, after throw out lyophilize for some time, be that 60 ℃ of following vacuum-dryings are to doing taking-up in temperature again, pulverize, get white powder.
2. ultrafiltration process: the extracting solution that gets relative density 1.08～1.25 (45-60 ℃) by 1 legal system is placed room temperature, and adding 95% medical ethanol to determining alcohol is 80%, places 8-16 hour (spending the night).Abandoning supernatant, with the dissolving of pure hypostasis water, be made into 1: 10 (pure hypostasis: suspension water), centrifugal, remove insolubles.Be that 40,000 Hollow Fiber Ultrafiltration post is removed relative molecular weight greater than 40,000 macromolecular substance such as natural gum with the relative molecular weight cutoff value earlier, flow velocity is 20ml/min, and pressure is 0.15 * 10
6Pa; Be that 3000 hollow fiber membrane ultrafiltration devices are removed relative molecular weight less than 3000 small-molecule substance with the relative molecular weight cutoff value again, flow velocity is 15ml/min, and pressure is 0.1 * 10
6Pa.Merge, concentrate relative molecular weight 3000～40,000 fractions, freezing, dry, get fragrant solomonseal rhizome polyoses.
The fragrant solomonseal rhizome polyoses that obtains with method of the present invention is white powder, and is water-soluble, is soluble in hot water especially, is insoluble to the ethanol and the acetone of high density, and the Molish reaction becomes positive with anthrone-strong sulfuric acid response, illustrate to contain polysaccharide in the white powder; Ninhydrin reaction is negative, and no protein is described.Do not contain monose after testing, molecular weight is that 3000～40,000 fragrant solomonseal rhizome polyoses becomes to hive off, and polysaccharide content is more than 98%.
The preparation method of fragrant solomonseal rhizome polyoses pharmaceutical preparation: the above-mentioned fragrant solomonseal rhizome polyoses that makes is added suitable auxiliary material, can be prepared into solid dosages such as tablet, capsule, granule, buccal tablet, chewable tablet, dispersible tablet class, also can be prepared into liquid dosage forms such as oral liquid, mixture class.
The preparation prescription and the technology of pharmaceutical preparation:
Capsule prescription (weight part): 50～300 parts of fragrant solomonseal rhizome polyoses
50～200 parts of micropowder silica gels
50～200 parts in dextrin
Micropowder silica gel, dextrin mixing with recipe quantity join in the polysaccharide of recipe quantity again, mixing, and vacuum-drying (vacuum tightness 0.08-0.09Mpa) is pulverized, mixing, encapsulated (zero～No. 2) get 1000 approximately.Every capsules weighs 0.15～0.7g, contains fragrant solomonseal rhizome polyoses 0.05 g～0.3g.
Tablet formulation (weight part):
50～300 parts of fragrant solomonseal rhizome polyoses
30～60 parts of hypromelloses (K4M)
50～240 parts of lactose
The 3% hypromellose aqueous solution is an amount of
1～5 part of Magnesium Stearate
Every heavy 0.13～0.60g, every contains fragrant solomonseal rhizome polyoses 0.05g～0.3g
Making step comprises in detail:
A, get fragrant solomonseal rhizome polyoses, lactose, hypromellose, Magnesium Stearate respectively and cross 120 mesh sieves, at 105 ℃ of baking 1h, standby.
B, take by weighing main ingredient, lactose, hypromellose by formula rate, thorough mixing is even;
C, add the roughly 3% hypromellose aqueous solution of recipe quantity, thorough mixing is even, the system softwood;
D, 16 mesh sieves are granulated, and 60 ℃ of dryings with the whole grain of order, add the Magnesium Stearate mixing, compressing tablet;
E, quality inspection, packing, signature, promptly.
Purposes of the present invention and service requirements: the present invention has extracted molecular weight from the radix polygonati officinalis medicinal material be 3000～40,000 fragrant solomonseal rhizome polyoses becomes to hive off, purity is more than 98%, above-mentioned polysaccharide is added suitable auxiliary material, solid dosages such as tablet, capsule, granule, buccal tablet, chewable tablet, dispersible tablet can be prepared into, also liquid dosage forms such as oral liquid, mixture can be prepared into.Hypoglycemic, particularly reducing blood-fat that the fragrant solomonseal rhizome polyoses medicament is used for to hyperlipidemia and hyperglycemia patient, can be played hypoglycemic and reducing blood lipid.Above preparation is all with the oral way administration.Usage and consumption: oral, take fragrant solomonseal rhizome polyoses 0.1～0.5g, three times on the one at every turn.
The present invention from radix polygonati officinalis separation and Extraction fragrant solomonseal rhizome polyoses, and it is prepared into oral administration solid or liquid preparation by certain requirement, can reduce blood sugar and the blood fat of hyperglycemia, hyperlipidemia animal, be applicable to diabetic subject and hyperlipemic patients.The present invention has confirmed the above-mentioned beneficial effect of the fragrant solomonseal rhizome polyoses of extraction with experimentation on animals described below.
(1) experimental study of fragrant solomonseal rhizome polyoses effect for reducing fat
1, materials and methods
1.1 laboratory animal
30 of purebred new zealand rabbits, half and half, 5 monthly age of male and female, body weight (2.4 ± 0.2) kg.Divide 5 groups at random: 3 groups of Xuezhikang group, Zocor group, 1 group of radix polygonati officinalis, 2 groups of radix polygonati officinalis and radix polygonati officinalis, 6 every group.
1.2 method
1.2.1 the foundation of hyperlipemia model adds 5% lard and 0.5% cholesterol nutrition purposes, especially for feeding animals with conventional feed, serum lipid concentrations was measured in fasting in 10 hours after 10 days, treat to give lipopenicillinase and experiment medicine after it has significant blood fat to raise, and keep high fat diet to experiment and finish.
1.2.2 medication Xuezhikang group: 300mgkg
-1D
-1Xuezhikang adds the dissolving of 40ml tap water, divides two inferior to feeding after the animal feed; Zocor group: 5mgkg
-1D
-1Zocor is dissolved in the 20ml tap water, once feeds after the animal feed; 1,2,3 groups of radix polygonati officinalis: respectively with 0.2g, 0.4g, 0.4gkg
-1D
-1Fragrant solomonseal rhizome polyoses be dissolved in the 40ml tap water, divide two inferior to feeding after the animal feed.
1.2.3 select 12 animal fasting to measure its blood-sugar content in 10 hours at random before the lipid determination experiment, to test last fasting and checked whole laboratory animal lipids contents in 10 hours, measuring method is the hour method.
1.2.4 all animals is put to death in aorta form and om observation experiment back, get its aorta and carry out general form and observe, and get its part aorta with 10% formaldehyde fixed after the paraffin look bury section, HE dyes and om observation.
1.3 statistical treatment
Experimental data represents that with x ± s statistical study is q check and a plurality of sample χ relatively that compares in twos between paired t-test, a plurality of mean
2Check.
2 results
2.1 animal lipid changes (table 1) after the hypercholesterolemia diet
Can find out that from table 1 after the hypercholesterolemia diet was fed, experimental animal CHO, LDL, Lp (a) all significantly raise, and have formed tangible hyperlipidaemia.
2.2 respectively organize the Blood Lipid (table 2) before and after the laboratory animal medication
Can find out that from table 2 blood fat CHO, LDL, Lp (a) concentration significantly reduce before and after 3 groups of treatments of fragrant solomonseal rhizome polyoses; Except that Lpa) descend, each index does not all have noticeable change before and after 1,2 groups of treatments of radix polygonati officinalis.
2.3 each treated animal Blood Lipid of experiment back is (table 3) relatively
The variation of serum lipid concentrations does not have significant difference between each treatment group of table 3 expression experiment end, illustrates that each group all has reducing blood lipid.
2.4 the situation of atherosclerosis of aorta
Have the visible a small amount of lipid striped of a routine sample aorta to form 2.4.1 general form is observed the Xuezhikang group, surplus laboratory animal there is no tangible lipid striped or atheromatous plaque forms.
2.4.2 om observation part laboratory animal aortic tunica intima sees that foam inner membrance in various degree forms, it the results are shown in Table 4.
Can find out that from table 4 fragrant solomonseal rhizome polyoses group aortic tunica intima foam cell forms and significantly is less than Xuezhikang group, Zocor group (P＜0.05), and be dose-dependence between each group of fragrant solomonseal rhizome polyoses group.
(2) experimental study of fragrant solomonseal rhizome polyoses blood sugar reducing function
1, materials and methods
1.1 laboratory animal
24 of BALB/C mice, at half and half, 2 monthly age of male and female, body weight (25.2 ± 2.4) g divides 4 groups: 1,2 groups of glipizide groups, TANGMAIKANG group, fragrant solomonseal rhizome polyoses, 6 every group at random.
1.2 method
1.2.1 the mouse peritoneal injection urea of setting up of diabetes model is helped rhzomorph 40mgkg
-1D
-1, continuous 5 days.Fasting was cut tail in 6 hours and is measured its blood-sugar content after 10 days, had treated to contrast and test medicine behind the obvious blood sugar increasing.
1.2.2 medication glipizide group: 8mgkg
-1D
-1Glipizide adds physiological saline 0.5ml dissolving, irritates stomach once a day and gives; TANGMAIKANG group: 12.5gkg
-1D
-1TANGMAIKANG adds the 1ml physiological saline solution, divides secondary to irritate stomach and gives, and 1,2 groups of fragrant solomonseal rhizome polyoses are respectively with 0.2g, 1gkg
-1.d
-1Fragrant solomonseal rhizome polyoses dissolve in physiological saline 1ml, divide secondary to irritate stomach and give.
1.2.3 select 3 animal fasting to cut tail after 6 hours at random to measure its blood-sugar content for every group before the detection method experiment, the same method test experience animal blood glucose content behind the injection streptozotocin is tested last fasting and was got the socket of the eye arterial blood in 6 hours and measure blood sugar and HbA
1CAmount.Detection method is respectively glucose oxidase method and chromatography column method.
1.3 statistical treatment
Experimental data represents that with x ± s statistical study is relatively q check in twos between paired t-test and a plurality of mean.
2 results
2.1 change of blood sugar (table 5) behind the laboratory animal injection streptozotocin
Can find out that from table 5 fasting plasma glucose significantly raises behind the experiment mice injection streptozotocin, has formed typical experimental diabetes disease model.
2.2 respectively organize laboratory animal treatment front and back change of blood sugar (table 6)
Can find out that from table 6 after fragrant solomonseal rhizome polyoses and glipizide treatment, FBS has significant differences (p＜0.01), TANGMAIKANG group treatment back FBS decline no significance meaning (P＞0.05).
2.3 experiment back each treated animal FBS and HbA
1CThe variation (table 7) of content
Can find out that from table 7 hypoglycemic effect of each treatment group does not relatively have significance meaning (P＞0.05); But radix polygonati officinalis reduces HbA for 1,2 groups
1cEffect and glipizide group and TANGMAIKANG group meaning (P＜0.01) that highly significant is relatively arranged.
Embodiment
The invention will be further described below in conjunction with embodiment.
Specific embodiment 1
Dry radix polygonati officinalis crude drug 9Kg is cut into small pieces, and places 10 times of water gagings, boils and extracts 1 hour, extracting liquid filtering, the dregs of a decoction add 10 times water in addition, boil and extract 1 hour, extracting liquid filtering merges centrifugal treating with No. 2 extracting solutions, get the supernatant liquor concentrating under reduced pressure,, be placed to room temperature to relative density 1.15 (50 ℃), it is 80% that the ethanol liquid of adding 95% makes it to contain the alcohol amount, stirring was left standstill 12 hours, separated taking precipitate, added 1.5 times of washings of cold distilled water, throw out heating dissolved in distilled water, adding 95% ethanol, to make it to contain alcohol amount be 70%, left standstill 12 hours, divides taking precipitate, with 95% washing with alcohol of 3 times of amounts three times, discard pure washing lotion, the throw out lyophilize is that 60 ℃ of following vacuum-dryings are to doing in temperature again after 12 hours, take out, pulverize, get white powder 340 grams, yield 3.8%, polysaccharide content is 98.6%.
Specific embodiment 2
Dry radix polygonati officinalis crude drug 10Kg is cut into small pieces, place 10 times of water gagings, boil and extracted 1 hour, extracting liquid filtering, the dregs of a decoction add 10 times water in addition, boil and extracted 1 hour, extracting liquid filtering merges No. 2 extracting solutions, centrifugal treating, get the supernatant liquor concentrating under reduced pressure,, be placed to room temperature to relative density 1.15 (50 ℃), it is 80% that the ethanol liquid of adding 95% makes it to contain the alcohol amount, left standstill 12 hours, and separated taking precipitate, add 1.5 times of washings of cold distilled water, with pure hypostasis water dissolving, be made into 1: 10 (pure hypostasis: suspension water), centrifugal, remove insolubles.Be that 40,000 Hollow Fiber Ultrafiltration post is removed relative molecular weight greater than 40,000 macromolecular substance such as natural gum with the relative molecular weight cutoff value earlier, flow velocity is 20ml/min, and pressure is 0.15 * 10
6Pa; Be that 3000 hollow fiber membrane ultrafiltration devices are removed relative molecular weight less than 3000 small-molecule substance with the relative molecular weight cutoff value again, flow velocity is 15ml/min, and pressure is 0.1 * 10
6Pa.Merge, concentrate relative molecular weight 3000～40,000 fractions, freezing, dry, get fragrant solomonseal rhizome polyoses 400 grams, yield 4.0%, polysaccharide content is 98.5%.
Specific embodiment 3
Capsule preparation: fragrant solomonseal rhizome polyoses 50g
Micropowder silica gel 50g
Dextrin 50g
Can make 1000 approximately
Micropowder silica gel, dextrin mixing with recipe quantity join in the polysaccharide of recipe quantity again, mixing, and vacuum-drying (vacuum tightness 0.08-0.09Mpa) is pulverized, mixing, encapsulated (No. 2) get 1000 approximately.The heavy 0.15g of every capsules, every contains fragrant solomonseal rhizome polyoses 0.05g.
Specific embodiment 4
Capsule preparation: fragrant solomonseal rhizome polyoses 300g
Micropowder silica gel 200g
Dextrin 200g
Make 1000 approximately
Micropowder silica gel, dextrin mixing with recipe quantity join in the polysaccharide of recipe quantity again, mixing, and vacuum-drying (vacuum tightness 0.08-0.09Mpa) is pulverized, mixing, encapsulated (No. zero) gets 1000 approximately.The heavy 0.7g of every capsules contains fragrant solomonseal rhizome polyoses 0.3g.
Specific embodiment 5
Tablet formulation, technology:
Fragrant solomonseal rhizome polyoses 50g
Hypromellose (K4M) 30g
Lactose 50g
The 3% hypromellose aqueous solution is an amount of
Magnesium Stearate 1g
Make 1000 altogether, every heavy 0.13g, every contains fragrant solomonseal rhizome polyoses 0.05g.
The detail operations step
1, get fragrant solomonseal rhizome polyoses, lactose, hypromellose, Magnesium Stearate respectively and cross 120 mesh sieves, at 105 ℃ of baking 1h, standby.
2, the prescription ratio takes by weighing main ingredient, lactose, hypromellose, and thorough mixing is even;
3, add the roughly 3% hypromellose aqueous solution of recipe quantity, thorough mixing is even, the system softwood;
4,16 mesh sieves are granulated, and 60 ℃ of dryings with the whole grain of order, add the Magnesium Stearate mixing, compressing tablet;
5, quality inspection, packing, signature, promptly.
Specific embodiment 6
Tablet formulation, technology:
Fragrant solomonseal rhizome polyoses 300g
Hypromellose (K4M) 60g
Lactose 240g
The 3% hypromellose aqueous solution is an amount of
Magnesium Stearate 5g
Make 1000 altogether, every heavy 0.60g, every contains fragrant solomonseal rhizome polyoses 0.3g
The detail operations step
1, get main ingredient, lactose, hypromellose, Magnesium Stearate respectively and cross 120 mesh sieves, at 105 ℃ of baking 1h, standby.
2, take by weighing main ingredient, lactose, hypromellose in the prescription ratio, thorough mixing is even;
3, add the roughly 3% hypromellose aqueous solution of recipe quantity, thorough mixing is even, the system softwood;
4,16 mesh sieves are granulated, and 60 ℃ of dryings with the whole grain of order, add the Magnesium Stearate mixing, compressing tablet;
5, quality inspection, packing, signature, promptly.
Usage and consumption: this product is oral, takes fragrant solomonseal rhizome polyoses 0.1～0.5g at every turn.
Animal lipid changes after table 1 high fat diet
| n | TG(mmol/L) | CHO(mmol/L) | HDL(mmol/L) | LDL(mmol/L) | Lp(a)(mg/L) | |
| Before the high fat diet | 12 | 0.68±0.23 | 1.38±0.27 | 0.63±0.13 | 0.46±0.20 | 163.7±25.3 |
| After the high fat diet | 30 | 0.41±0.12 | 11.32±1.34 * | 0.91±0.14 | 9.18±124 * | 681.5±124.3 * |
*P＜0.01
Blood Lipid before and after each experimental group treatment of table 2
| n | TG | CHO | HDL | LDL | Lp(a) | ||||||
| Before the treatment | After the treatment | Before the treatment | After the treatment | Before the treatment | After the treatment | Before the treatment | After the treatment | Before the treatment | After the treatment | ||
| The Xuezhikang group | 6 | 0.39±0.67 | 0.27±0.07 | 11.45±1.67 | 8.33±5.12 | 0.85±0.14 | 1.14±0.36 | 10.25±2.12 | 7.31±5.25 | 752.4±111.3 | 37.4±10.5 * |
| The Zocor group | 6 | 0.46±0.15 | 0.37±0.10 | 10.73±1.54 | 6.41±3.66 △ | 0.81±0.08 | 0.97±0.22 | 9.87±1.41 | 5.24±3.52 △ | 727.1±125.3 | 477+12.8 * |
| 1 group of radix polygonati officinalis | 6 | 0.48±0.08 | 0.53±0.12 | 11.21±1.21 | 12.4±5.84 | 0.78±0.08 | 0.66±0.21 | 9.48±1.32 | 10.36±5.48 | 613.5±137.3 | 44.7+8.6 * |
| 2 groups of radix polygonati officinalis | 6 | 0.54±0.06 | 0.41±0.23 | 10.92±1.38 | 6.83±3.87 | 0.84±0.14 | 1.46±0.27 | 9.56±1.24 | 5.27±3.13 △ | 652.8±134.8 | 49.6+2.4 * |
| 3 groups of radix polygonati officinalis | 6 | 0.51±0.06 | 0.69±0.31 | 11.71±1.75 | 5.42±1.63 * | 0.87±0.12 | 1.62±0.43 | 10.63±1.48 | 4.51±1.34 * | 640.5±107.8 | 35.8+13.1 * |
It is relatively preceding with treatment,
*P＜0.01,
△P＜0.05
Each treated animal Blood Lipid of table 3 experiment back relatively
| n | TG | CHO | HDL | LDL | Lp(a) | |
| The Xuezhikang group | 6 | 0.27±0.07 | 8.33±5.12 | 1.14±0.36 | 7.31±5.25 | 37.4±10.5 |
| The Zocor group | 6 | 0.37±0.10 | 6.41±3.66 | 0.97±0.22 | 5.24±3.52 | 47.7±12.8 |
| 1 group of radix polygonati officinalis | 6 | 0.53±0.12 | 12.47±5.84 | 0.66±0.21 | 10.36±5.48 | 44.7±8.6 |
| 2 groups of radix polygonati officinalis | 6 | 0.41±0.23 | 6.83±3.87 | 1.46±0.27 | 5.27±3.13 | 49.6±12.4 |
| 3 groups of radix polygonati officinalis | 6 | 0.69±0.31 | 5.42±1.63 | 1.62±0.43 | 4.51±1.34 | 35.8±12.1 |
P all＞0.05
Table 4 aortic tunica intima foam cell forms situation
| Grouping | The test samples number | Add up to | Incidence | |
| There is foam cell to form | The non-foam cell forms | |||
| The Xuezhikang group | 5 | 1 | 6 | 83.3％ |
| The Zocor group | 3 | 3 | 6 | 50％ |
| 1 group of radix polygonati officinalis | 2 | 4 | 6 | 33.3％ |
| 2 groups of radix polygonati officinalis | 1 | 5 | 6 | 16.7％ * |
| 3 groups of radix polygonati officinalis | 1 | 5 | 6 | 16.7％ * |
Compare for 1 group with Xuezhikang group, Zocor group, radix polygonati officinalis,
*P＜0.05
Table 5 experimental diabetic animal change of blood sugar
| n | FBS(mmol/L) | The P value | |
| Before the injection | 12 | 5.83±0.44 | 0.001 |
| After the injection | 24 | 9.14±0.82 |
Change of blood sugar before and after each experimental group medication of table 6
| n | FBS(mmol/L) | The P value | |
| Before the treatment | After the treatment | ||
| Glipizide group 6 | 8.71±0.54 | 6.12±0.93 | 0.001 |
| TANGMAIKANG group 6 | 8.21±0.37 | 7.47±2.03 | 0.587 |
| 1 group 6 of radix polygonati officinalis | 9.22±0.61 | 6.17±0.94 | 0.001 |
| 2 group 6 of radix polygonati officinalis | 8.84±0.46 | 7.37±0.45 | 0.005 |
Respectively organize FBS, HbA after table 7 experiment
1CContent
| n | FBS(mmol/L) | HbA 1C(％) | |
| The glipizide group | 6 | 6.18±0.87 * | 3.08±0.36 |
| The TANGMAIKANG group | 6 | 7.52±2.18 * | 3.23±0.16 |
| 1 group of radix polygonati officinalis | 6 | 6.33±1.12 * | 2.31±0.33 △ |
| 2 groups of radix polygonati officinalis | 6 | 7.25±0.38 * | 1.94±0.27 △ |
*Compare P＞0.05 between each group
△ and glipizide group and TANGMAIKANG group compare, P＜0.01
Claims (6)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100228635A CN1330670C (en) | 2004-02-02 | 2004-02-02 | Process for extracting polygonatum polysaccharides, preparing process for medical preparation and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100228635A CN1330670C (en) | 2004-02-02 | 2004-02-02 | Process for extracting polygonatum polysaccharides, preparing process for medical preparation and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1557842A CN1557842A (en) | 2004-12-29 |
| CN1330670C true CN1330670C (en) | 2007-08-08 |
Family
ID=34352102
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100228635A Expired - Fee Related CN1330670C (en) | 2004-02-02 | 2004-02-02 | Process for extracting polygonatum polysaccharides, preparing process for medical preparation and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1330670C (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7378513B2 (en) * | 2005-07-26 | 2008-05-27 | The Chinese University Of Hong Kong | Isolated proteins from a traditional Chinese medicine Yuzhu and use thereof |
| CN101129400B (en) * | 2006-08-23 | 2010-12-08 | 周亚伟 | Application of Polysaccharides from Polygonatum Polygonatum in Preparation of Drugs for Treating Coronary Heart Disease |
| CN101574475B (en) * | 2009-06-18 | 2012-08-29 | 中南大学 | Polygonatum particle and preparation method thereof |
| CN101579116B (en) * | 2009-06-23 | 2013-04-03 | 宽甸玉竹农副产品有限公司 | Polygonatum odoratum health-care food |
| CN101580551B (en) * | 2009-06-23 | 2011-11-30 | 宽甸玉竹农副产品有限公司 | Method for extracting polygonatum odoratum polysaccharide |
| KR100956278B1 (en) * | 2009-08-03 | 2010-05-10 | 대한약품공업 주식회사 | Composition comprising an extract of herbal combination thereof for preventing and treating diabetes mellitus |
| CN101857644B (en) * | 2010-05-24 | 2012-10-03 | 广西大学 | Alcohol alkali extraction method of aspartic polysaccharide and production process |
| CN102755266A (en) * | 2011-04-26 | 2012-10-31 | 上海家化联合股份有限公司 | Chinese herbal medicine extract, preparation method thereof, and application thereof |
| CN102703444B (en) * | 2012-05-25 | 2013-08-14 | 安徽师范大学 | Radix polygonati officinalis microsatellite DNA (deoxyribonucleic acid) molecular marker |
| CN104069347A (en) * | 2014-06-30 | 2014-10-01 | 吉林化工学院 | Preparation method of polygonatum odoratum total saponin dispersible tablet |
| CN105194319A (en) * | 2015-11-08 | 2015-12-30 | 长沙佰顺生物科技有限公司 | Preparation method of polygonatum odoratum polysaccharide medicine composition |
| CN108359023A (en) * | 2018-03-02 | 2018-08-03 | 北京国康本草物种生物科学技术研究院有限公司 | A kind of extracting method and fragrant solomonseal rhizome polyoses extract of fragrant solomonseal rhizome polyoses |
| CN111345424A (en) * | 2020-04-14 | 2020-06-30 | 吉林农业科技学院 | Polygonatum odoratum polysaccharide solid beverage and purification process |
| CN116675782A (en) * | 2023-05-17 | 2023-09-01 | 宁波大学科学技术学院 | Method for extracting polygonatum odoratum polysaccharide and determination method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1220890A (en) * | 1998-10-16 | 1999-06-30 | 朱旭 | Pure natural biological preparation for treating diabetes and preparation method thereof |
| CN1398901A (en) * | 2001-07-19 | 2003-02-26 | 中国科学院成都生物研究所 | Prepn and use of curcuma oligosaccharide sulfate derivative |
-
2004
- 2004-02-02 CN CNB2004100228635A patent/CN1330670C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1220890A (en) * | 1998-10-16 | 1999-06-30 | 朱旭 | Pure natural biological preparation for treating diabetes and preparation method thereof |
| CN1398901A (en) * | 2001-07-19 | 2003-02-26 | 中国科学院成都生物研究所 | Prepn and use of curcuma oligosaccharide sulfate derivative |
Non-Patent Citations (4)
| Title |
|---|
| 抗粮尿病中药开发前景展望 陈广耀，中国新药杂志，第9卷第7期 2000 * |
| 生药材调节血糖有效成分的研究 侯昕、徐峰、刘根节、鲍丛荫，辽宁实用糖尿病杂志，第11卷第1期 2003 * |
| 黄精玉竹及其制剂的药理学研究进展 刘玉萍，付桂芳，曹晖，时珍国医国药，第9卷第4期 1998 * |
| 黄精玉竹及其制剂的药理学研究进展 刘玉萍，付桂芳，曹晖，时珍国医国药，第9卷第4期 1998;抗粮尿病中药开发前景展望 陈广耀，中国新药杂志，第9卷第7期 2000;生药材调节血糖有效成分的研究 侯昕、徐峰、刘根节、鲍丛荫，辽宁实用糖尿病杂志，第11卷第1期 2003 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1557842A (en) | 2004-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1330670C (en) | Process for extracting polygonatum polysaccharides, preparing process for medical preparation and use thereof | |
| CN101862351B (en) | Application of active parts of nutgall in preparing medicine for resisting ulcerative colitis | |
| CN102430090A (en) | Traditional Tibetan medicine Ruyizhenbao composite preparation and preparation method thereof | |
| CN102526219B (en) | Extract for Relinqing Granule, as well as preparation method and application of same | |
| CN102813765A (en) | Method for preparing Zhixinkang preparation | |
| CN1558768A (en) | A pharmaceutical composition made from Chinese traditional medicine and preparation method thereof | |
| CN102319357B (en) | Lipid-lowering dispersible tablets and preparation technology thereof | |
| CN101849950A (en) | Application of rotundic acid in preparing blood lipid regulating medicines | |
| CN104857154A (en) | Traditional Chinese medicine composition for treating three-high diseases and preparation method therefor | |
| CN100477996C (en) | Extract of star of bethlehem and its prepn process, medicinal composition and use | |
| CN1985922B (en) | Medicine composition for treating common cold and its preparing method | |
| CN104042684B (en) | A kind of Chinese medicine composition containing Herb Gynostemmae Pentaphylli extract and preparation method | |
| CN113730464A (en) | New application of rhizoma coptidis pill, extract and pharmaceutical composition thereof and rhizoma coptidis pill product | |
| CN105943617A (en) | Application of whole hemp extract in preparation of anti-hepatitis drugs | |
| JP7340113B2 (en) | Chinese herbal composition and its production method and use | |
| CN112057535B (en) | Preparation method of traditional Chinese medicine composition for preventing or/and treating dyslipidemia | |
| CN1969963A (en) | Method for extracting medicament effective component for treating hepatitis and medicinal composition thereof | |
| CN103933386B (en) | Compound hemophiliac capsule used for treating hemophilia and preparation method thereof | |
| CN103505664A (en) | Blood lipid reducing composition containing semen cassiae and preparation method of composition | |
| CN103083429A (en) | Blood fat-reducing traditional Chinese medicine formula | |
| CN100355448C (en) | Chinese traditional medicine compound preparation for preventing and curing alcoholic intestinal tract and liver injury | |
| CN112675271A (en) | Traditional Chinese medicine composition for treating internal abnormality and application thereof | |
| CN1985909A (en) | Medicine for hyperlipemia and its production process | |
| CN110101792A (en) | Chinese medicine composition and its preparation method and application with effect for reducing fat | |
| CN112057536B (en) | Traditional Chinese medicine composition for preventing or/and treating dyslipidemia and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070808 Termination date: 20110202 |